Spatial oligonucleotide immuno-reprogramming model provides a conceptual research framework for multiple myeloma studyNew Research Framework Explores Oligonucleotides for Multiple Myeloma Treatment

This narrative review presents SOIRM as a conceptual and testable research framework rather than a systematic review, a report of new experimental data, or an established treatment model. It distinguishes findings supported by multiple myeloma studies from emerging evidence, the author’s interpretation, and hypotheses that require dedicated experimental and clinical validation. Therapeutic resistance and measurable residual disease (MRD) in multiple myeloma (MM) reflect tumor-intrinsic evolution and interactions between malignant plasma cells and the bone marrow microenvironment. Recent primary studies have identified inflammatory stromal populations, subclone-specific effects on the microenvironment, site-specific plasma-cell programs, and immune states associated with treatment response. These findings do not yet establish a clinically applicable spatially targeted intervention. The Spatial Oligonucleotide Immuno-Reprogramming Model (SOIRM) is therefore proposed as a falsifiable research framework, not as an established therapy.